TY - JOUR
T1 - Relaxant effect of human brain natriuretic peptide on human artery and vein tissue
AU - Protter, Andrew A.
AU - Wallace, Annette M.
AU - Ferraris, Victor A.
AU - Weishaar, Ronald E.
PY - 1996/5
Y1 - 1996/5
N2 - Brain natriuretic peptide (BNP) is a cardiac-derived peptide hormone with cardiovascular and renal actions that is structurally and functionally related to atrial natriuretic peptide (ANP). Previous studies using rat vascular tissue have demonstrated a direct vasorelaxant effect of BNP. However, species-specific potency issues have precluded an accurate measurement of the effect of human BNP. This report demonstrates the vasorelaxant effects of human BNP on human vascular tissue prepared from internal mammary artery and saphenous vein samples. The vasorelaxant effect of human BNP is compared to the other members of the natriuretic peptide family, human ANP and C-type natriuretic peptide (CNP). With regard to potency and magnitude of effect, human BNP and human ANP were similar in relaxing arterial tissue preconstricted with endothelin-1 (BNP ED50 = 1.9 nmol/L and ANP ED50 = 1.8 nmol/L) or phenylephrine (BNP ED50 = 10 nmol/L and ANP ED50 = 19 nmol/L), while CNP was significantly less effective. All three natriuretic peptides exhibited weak venodilating action. These data demonstrate that human BNP is a potent inhibitor of the vasoconstrictive actions of endothelin-1 and the α-adrenergic agonist phenylephrine on isolated human artery tissue preparations.
AB - Brain natriuretic peptide (BNP) is a cardiac-derived peptide hormone with cardiovascular and renal actions that is structurally and functionally related to atrial natriuretic peptide (ANP). Previous studies using rat vascular tissue have demonstrated a direct vasorelaxant effect of BNP. However, species-specific potency issues have precluded an accurate measurement of the effect of human BNP. This report demonstrates the vasorelaxant effects of human BNP on human vascular tissue prepared from internal mammary artery and saphenous vein samples. The vasorelaxant effect of human BNP is compared to the other members of the natriuretic peptide family, human ANP and C-type natriuretic peptide (CNP). With regard to potency and magnitude of effect, human BNP and human ANP were similar in relaxing arterial tissue preconstricted with endothelin-1 (BNP ED50 = 1.9 nmol/L and ANP ED50 = 1.8 nmol/L) or phenylephrine (BNP ED50 = 10 nmol/L and ANP ED50 = 19 nmol/L), while CNP was significantly less effective. All three natriuretic peptides exhibited weak venodilating action. These data demonstrate that human BNP is a potent inhibitor of the vasoconstrictive actions of endothelin-1 and the α-adrenergic agonist phenylephrine on isolated human artery tissue preparations.
KW - Brain natriuretic peptide
KW - Catecholamines
UR - http://www.scopus.com/inward/record.url?scp=0029977756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029977756&partnerID=8YFLogxK
U2 - 10.1016/0895-7061(95)00435-1
DO - 10.1016/0895-7061(95)00435-1
M3 - Article
C2 - 8735173
AN - SCOPUS:0029977756
SN - 0895-7061
VL - 9
SP - 432
EP - 436
JO - American Journal of Hypertension
JF - American Journal of Hypertension
IS - 5
ER -